ReviewBioMed research international2015
Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Investigation and systematic review of temporal associations between vaccination and onset of immune-mediated hemolytic anemia or thrombocytopenia in dogs.Journal of veterinary internal medicine · 2026Pooled it
- Trial
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Three Faces of Self-Destruction: A Case Series of Warm, Cold, and Mixed Autoimmune Hemolytic Anemia.Cureus · 2026Article
- Combined FXIII-C3 autoantibodies elicit bleeding and complement dysfunction in autoimmune FXIII deficiency.The Journal of clinical investigation · 2026Article
- Cold versus warm autoimmune hemolytic anemia in diffuse large B cell lymphoma: pathogenic and therapeutic implications: a case series.Journal of medical case reports · 2025Article
- From Yellow Cumulus to Pregnancy in Autoimmune Hemolytic Anemia Following Bilirubin Reduction: A Case Report.Cureus · 2025Article
- A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report.Frontiers in immunology · 2025Article
- Adult-onset severe paroxysmal cold hemoglobinuria after COVID-19 successfully treated with sutimlimab.International journal of hematology · 2024Article
- Investigating the Impact of Cold Agglutinins on Red Blood Cell Parameters in a Trauma Patient.Cureus · 2024Article
- Warm Autoimmune Hemolytic Anemia Secondary to Babesia Microti Infection: A Case Report.Cureus · 2023Article
- Future prospects for the clinical transfusion of pig red blood cells.Blood reviews · 2023Review
- The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation.Clinical & translational immunology · 2023Article
- Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.BMJ case reports · 2022Article
- The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.JMIR formative research · 2022Article
- The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19.Immunobiology · 2022Article
- Complement-mediated autoimmune haemolytic anaemia as an initial presentation of Legionnaires' disease.BMJ case reports · 2021Article
- Minimalistic In Vitro Culture to Drive Human Naive B Cell Differentiation into Antibody-Secreting Cells.Cells · 2021Article
- Acute Kidney Injury Caused by Evans Syndrome with Systemic Lupus Erythematosus and Systemic Sclerosis.Internal medicine (Tokyo, Japan) · 2021Article
- Changes in Complement Levels and Activity of Red Blood Cells, Fresh Frozen Plasma, and Platelet Concentrates During Storage.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemia (AIHA) is a collective term for several diseases characterized by autoantibody-initiated destruction of red blood cells (RBCs). Exact subclassification is essential. We provide a review of the respective types of AIHA with emphasis on mechanisms of RBC destruction, focusing in particular on complement involvement. Complement activation plays a definitive but limited role in warm-antibody AIHA (w-AIHA), whereas primary cold agglutinin disease (CAD), secondary cold agglutinin syndrome (CAS), and paroxysmal cold hemoglobinuria (PCH) are entirely complement-dependent disorders. The details of complement involvement differ among these subtypes. The theoretical background for therapeutic complement inhibition in selected patients is very strong in CAD, CAS, and PCH but more limited in w-AIHA. The optimal target complement component for inhibition is assumed to be important and highly dependent on the type of AIHA. Complement modulation is currently not an evidence-based therapy modality in any AIHA, but a number of experimental and preclinical studies are in progress and a few clinical observations have been reported. Clinical studies of new complement inhibitors are probably not far ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.